Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
about
Sorafenib in metastatic thyroid cancer: a systematic reviewRAS mutations in thyroid cancerThe role of Cdk5 in neuroendocrine thyroid cancerCorrelative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupPrognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Cutaneous metastasis of medullary carcinoma thyroid masquerading as subcutaneous nodules anterior chest and mandibular region.Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In VivoExomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinomaOverexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancerIn vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.The Role of STAT3 in Thyroid Cancer.Medullary thyroid carcinoma: a 25-year perspective.New therapeutic options for advanced forms of thyroid cancer.Thyroid C-Cell Biology and Oncogenic Transformation.Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.Putative BRAF activating fusion in a medullary thyroid cancer.Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.Recent advances in the biology and therapy of medullary thyroid carcinoma.Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.Transcriptional targeting of oncogene addiction in medullary thyroid cancer
P2860
Q26828884-27780BDE-E1D9-4867-BB1B-EC2D62C3A516Q27026163-155DC8BC-162A-43C3-8FD1-FA42BC4CADE0Q28392185-4F23B79E-62B9-40D3-8D2F-7FEE60E6AE6DQ33587905-05FC902B-2A66-4142-BA84-3A60DAA0AEFAQ33813776-0414EFC6-7BE7-45EC-8110-C330E7A3E779Q34468665-816576DE-2E16-4328-A3C3-5670B8D915C3Q34575327-420F4086-7EDE-4642-9E05-055B09A7FCFBQ34821265-F1CD9DB6-7DBD-4EB5-86A4-0B6A61F735C5Q35044902-2B5F4D4E-0DC0-4E99-9400-9991552E7A1FQ35672203-F324A2AE-4406-4214-BDA4-7A2F018DE27CQ36489199-A5DD9894-C8B5-4B64-A008-C5EECFC0BD58Q36589374-A5662458-3EC2-4C72-92FF-7125AE0AB4CEQ36736460-7F37564E-7096-4EB8-BFA8-ADDDA83D9FFFQ36975457-0FA845C5-D058-4C08-B480-994D4C582F5BQ37015623-E05D5DEF-A6AF-4C96-B29A-0D0835E23379Q37290956-60FE987B-5655-44B1-B42F-1B9DE673888CQ37403891-E5B3EDBF-61A4-44E1-8EA9-A98B70EC20F0Q37633558-538C29B6-6F94-44CD-A9CC-E71900FA5131Q37693498-0ABE8C83-7586-4BC6-BA9C-43FBE6EFDA06Q38171726-76CABC94-1830-4936-B821-D062745242F6Q38192680-1DE7E1EE-FA08-4812-ABC8-5DBF2ED8EFFEQ38614485-27A09ED1-7935-4F3A-B5FF-D278ACFAA717Q38704670-2FFD29BA-BB3A-40D0-AB5C-B308C8918A34Q38883187-D5C767AD-D339-49AF-9175-A1F0227A5D47Q39020838-4D8969E0-E238-4A72-BC2F-7B67C9738F40Q39374983-E3ECB9E2-134E-490A-8F78-9C551A35109AQ40776672-1782D214-FB8B-40BE-92E1-8140823A6D80Q41251561-7BC3300C-F777-4C35-8E19-E1827860608FQ45998322-B925C0D0-A27E-4EBA-99CE-2B4A2773FA40Q47438629-6A66F91C-7157-4524-A49A-9CBDC3EDA0CCQ48246978-B7B64435-9E85-4847-AF50-50F0319D6CC2Q51662748-BD51B20F-ECC4-4783-BD6C-1FD696E42AA6Q58710816-12B6BE80-AFCF-4128-884C-0A35219F7912
P2860
Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Somatic RAS mutations occur in ...... previously unidentified exon.
@ast
Somatic RAS mutations occur in ...... previously unidentified exon.
@en
type
label
Somatic RAS mutations occur in ...... previously unidentified exon.
@ast
Somatic RAS mutations occur in ...... previously unidentified exon.
@en
prefLabel
Somatic RAS mutations occur in ...... previously unidentified exon.
@ast
Somatic RAS mutations occur in ...... previously unidentified exon.
@en
P2093
P2860
P356
P1476
Somatic RAS mutations occur in ...... a previously unidentified exon
@en
P2093
A Al Ghuzlan
A Boichard
J M Bidart
M Schlumberger
S Leboulleux
P2860
P304
P356
10.1210/JC.2012-2092
P407
P577
2012-08-03T00:00:00Z